Three biopharma companies became publicly traded companies and made their debut on the Nasdaq this week.
Cerevel Therapeutics began trading on the Nasdaq.
Neurotrope and Metuchen Pharmaceuticals announced the companies have merged in an all-stock deal to form Petros Pharmaceuticals, which is focused on men’s health conditions.
Amgen filed a Worker Adjustment and Retraining in California with plans to cut 172 jobs at the company’s headquarters and U.S. field operations effective December 31, 2019.